Kangsheng Gu
Jiangnan University(CN)Shanghai University(CN)Nanjing University of Chinese Medicine(CN)Harbin Engineering University(CN)Hohai University(CN)Guizhou University(CN)Anhui Medical University(CN)Heidelberg University(DE)University Hospital Heidelberg(DE)Blacktown & Mount Druitt Hospital(AU)Sichuan Agricultural University(CN)Soochow University(CN)Jilin Jianzhu University(CN)Ministry of Agriculture(ID)First Affiliated Hospital of Anhui Medical University(CN)Ministry of Agriculture and Rural Affairs(CN)Ministry of Industry and Information Technology(CN)South China University of Technology(CN)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, Lung Cancer Treatments and Mutations, Gastric Cancer Management and Outcomes, Colorectal Cancer Treatments and Studies, Esophageal Cancer Research and Treatment
Most-Cited Works
- → Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma(2021)773 cited
- → Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study(2023)612 cited
- → Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study(2020)575 cited
- → Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial(2020)556 cited
- → Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial(2020)492 cited